|
1
|
Stebbing J and Ellis P: An overview of
drug development for metastatic breast cancer. Br J Nurs. 21(Suppl
4): S18–S22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sampieri K and Fodde R: Cancer stem cells
and metastasis. Semin Cancer Biol. 22:187–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neumeister V, Agarwal S, Bordeaux J, Camp
RL and Rimm DL: In situ identification of putative cancer stem
cells by multiplexing ALDH1, CD44, and cytokeratin identifies
breast cancer patients with poor prognosis. Am J Pathol.
176:2131–2138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak
J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marhaba R, Klingbeil P, Nuebel T,
Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM:
Cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nomura M, Fukuda T, Fujii K, Kawamura T,
Tojo H, Kihara M, Bando Y, Gazdar AF, Tsuboi M, Oshiro H, et al:
Preferential expression of potential markers for cancer stem cells
in large cell neuroendocrine carcinoma of the lung. An FFPE
proteomic study. J Clin Bioinforma. 1:232011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng D, Wang N, Hu J and Li W: Surface
markers of hepatocellular cancer stem cells and their clinical
potential. Neoplasma. 61:505–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009. View Article : Google Scholar
|
|
10
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar
|
|
11
|
Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF,
Yang XJ, Zhang X, Cui YH, Bian XW and Yu SC: ALDH1A1 expression
correlates with clinicopathologic features and poor prognosis of
breast cancer patients: A systematic review and meta-analysis. BMC
Cancer. 14:4442014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu S, Xue W, Huang X, Yu X, Luo M, Huang
Y, Liu Y, Bi Z, Qiu X and Bai S: Distinct prognostic values of
ALDH1 isoenzymes in breast cancer. Tumour Biol. 36:2421–2426. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pandrangi SL, Chikati R, Chauhan PS, Kumar
CS, Banarji A and Saxena S: Effects of ellipticine on
ALDH1A1-expressing breast cancer stem cells - an in vitro and in
silico study. Tumour Biol. 35:723–737. 2014. View Article : Google Scholar
|
|
14
|
Sládek NE, Kollander R, Sreerama L and
Kiang DT: Cellular levels of aldehyde dehydrogenases (ALDH1A1 and
ALDH3A1) as predictors of therapeutic responses to
cyclophosphamide-based chemotherapy of breast cancer: A
retrospective study. Rational individualization of
oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer
Chemother Pharmacol. 49:309–321. 2002. View Article : Google Scholar
|
|
15
|
Condello S, Morgan CA, Nagdas S, Cao L,
Turek J, Hurley TD and Matei D: β-catenin-regulated ALDH1A1 is a
target in ovarian cancer spheroids. Oncogene. 34:2297–2308. 2015.
View Article : Google Scholar
|
|
16
|
Jiang W and Hiscox S: β-catenin - cell
adhesion and beyond (Review). Int J Oncol. 11:635–641.
1997.PubMed/NCBI
|
|
17
|
Madjd Z, Gheytanchi E, Erfani E and
Asadi-Lari M: Application of stem cells in targeted therapy of
breast cancer: A systematic review. Asian Pac J Cancer Prev.
14:2789–2800. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lindvall C, Bu W, Williams BO and Li Y:
Wnt signaling, stem cells, and the cellular origin of breast
cancer. Stem Cell Rev. 3:157–168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B,
Wen Y, Pestell RG and Hung MC: Beta-catenin, a novel prognostic
marker for breast cancer: Its roles in cyclin D1 expression and
cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu Z, Xiao Q, Zhao L, Ren J, Bai X, Sun M,
Wu H, Liu X, Song Z, Yan Y, et al: DNA methyltransferase 1/3a
overexpression in sporadic breast cancer is associated with reduced
expression of estrogen receptor-alpha/breast cancer susceptibility
gene 1 and poor prognosis. Mol Carcinog. Jan 25–2014.Epub ahead of
print. View
Article : Google Scholar
|
|
22
|
Fang Y, Wei J, Cao J, Zhao H, Liao B, Qiu
S, Wang D, Luo J and Chen W: Protein expression of ZEB2 in renal
cell carcinoma and its prognostic significance in patient survival.
PLoS One. 8:e625582013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ,
Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX, et al: Overexpression
of EIF5A2 promotes colorectal carcinoma cell aggressiveness by
upregulating MTA1 through C-myc to induce
epithelial-mesen-chymaltransition. Gut. 61:562–575. 2012.
View Article : Google Scholar
|
|
24
|
Khoury T, Ademuyiwa FO, Chandrasekhar R,
Jabbour M, Deleo A, Ferrone S, Wang Y and Wang X: Aldehyde
dehydrogenase 1A1 expression in breast cancer is associated with
stage, triple negativity, and outcome to neoadjuvant chemotherapy.
Mod Pathol. 25:388–397. 2012. View Article : Google Scholar :
|
|
25
|
Teng HW, Yang SH, Lin JK, Chen WS, Lin TC,
Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, et al: CIP2A is a
predictor of poor prognosis in colon cancer. J Gastrointest Surg.
16:1037–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y,
Uraoka N, Anami K, Sentani K, Oue N and Yasui W: Expression of
cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and
lymph node metastasis of gastric cancer. Pathol Int. 62:112–119.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Avoranta ST, Korkeila EA, Ristamäki RH,
Syrjänen KJ, Carpén OM, Pyrhönen SO and Sundström JT: ALDH1
expression indicates chemotherapy resistance and poor outcome in
node-negative rectal cancer. Hum Pathol. 44:966–974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Howe LR and Brown AM: Wnt signaling and
breast cancer. Cancer Biol Ther. 3:36–41. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
López-Knowles E, Zardawi SJ, McNeil CM,
Millar EK, Crea P, Musgrove EA, Sutherland RL and O'Toole SA:
Cytoplasmic localization of beta-catenin is a marker of poor
outcome in breast cancer patients. Cancer Epidemiol Biomarkers
Prev. 19:301–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dolled-Filhart M, McCabe A, Giltnane J,
Cregger M, Camp RL and Rimm DL: Quantitative in situ analysis of
beta-catenin expression in breast cancer shows decreased expression
is associated with poor outcome. Cancer Res. 66:5487–5494. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geyer FC, Lacroix-Triki M, Savage K,
Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho JS:
β-catenin pathway activation in breast cancer is associated with
triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol.
24:209–231. 2011. View Article : Google Scholar
|
|
32
|
Wang S, Li W, Lv S, Wang Y, Liu Z, Zhang
J, Liu T and Niu Y: Abnormal expression of Nek2 and β-catenin in
breast carcinoma: Clinicopathological correlations. Histopathology.
59:631–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barker N: The canonical Wnt/beta-catenin
signalling pathway. Methods Mol Biol. 468:5–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ozaki S, Ikeda S, Ishizaki Y, Kurihara T,
Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M and Asahara T:
Alterations and correlations of the components in the Wnt signaling
pathway and its target genes in breast cancer. Oncol Rep.
14:1437–1443. 2005.PubMed/NCBI
|
|
35
|
Schlosshauer PW, Brown SA, Eisinger K, Yan
Q, Guglielminetti ER, Parsons R, Ellenson LH and Kitajewski J: APC
truncation and increased beta-catenin levels in a human breast
cancer cell line. Carcinogenesis. 21:1453–1456. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Debeb BG, Lacerda L, Xu W, Larson R,
Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben
JM, et al: Histone deacetylase inhibitors stimulate
dedifferentiation of human breast cancer cells through
WNT/β-catenin signaling. Stem Cells. 30:2366–2377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu SL, Zeng DZ, Dong WG, Ding YQ, Rao J,
Duan JJ, Liu Q, Yang J, Zhan N, Liu Y, et al: Distinct patterns of
ALDH1A1 expression predict metastasis and poor outcome of
colorectal carcinoma. Int J Clin Exp Pathol. 7:2976–2986.
2014.PubMed/NCBI
|
